Retatrutide shows significant weight loss in diabetes clinical trials

Clinical trial results for Eli Lilly’s investigational triple agonist, retatrutide, show significant weight loss and metabolic improvements in adults with obesity and type 2 diabetes. Findings from the Phase III TRIUMPH-2 study, published in The Lancet, indicate that participants receiving the highest 12 mg dose achieved an average weight reduction of approximately 18.8% to 23.4%, depending on the specific study cohort and BMI.

Unlike previous GLP-1 or dual-agonist medications, retatrutide targets three hormone receptors: GLP-1, GIP, and glucagon. This mechanism is credited with enhancing appetite suppression and increasing energy expenditure. Beyond weight loss, the drug demonstrated improvements in glycemic control, with many participants reaching normal A1C levels, and reductions in cardiovascular risk factors such as triglycerides, cholesterol, and blood pressure.

Additional studies, including TRIUMPH-1, suggest potential secondary benefits, such as reduced pain in patients with knee osteoarthritis and fewer apnea-hypopnea events in those with obstructive sleep apnea. Common adverse effects reported were primarily gastrointestinal, including nausea, diarrhea, and vomiting, which were mostly mild to moderate in intensity.